Cetuximab for the treatment of advanced non-small cell lung cancer
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 December 2007
Topic area
  • Cancer
  • Respiratory

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: Liverpool Reviews and Implementation Group
Communications manager: Alice Law
Project manager: Lori Farrar
Technical Lead: Christian Griffiths


Manufacturers/sponsors Merck-Serono (cetuximab)
Others Aneurin Bevan LHB
  Department of Health
  Lancashire PCT Cluster
  Welsh Government
Patient/carer groups Afiya Trust
  Black Health Agency
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  Counsel and Care
  Equalities National Council
  Helen Rollason Heal Cancer Charity
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  Muslim Health Network
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Association for Services to the Elderly
  British Geriatrics Society
  British Psychosocial Oncology Society
  British Thoracic Society
  Cancer Networks Pharmacists Forum
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Primary Care Respiratory Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine – Intellectual Disabilities Forum
  United Kingdom Clinical Pharmacy Association
  United Kingdom Oncology Nursing Society (UKONS)
Associated guideline groups National Collaborating Centre for Cancer
Associated public health groups None
Evidence Review Group Liverpool Reviews & Implementation Group, University of Liverpool
  National Institute for Health Research Health Technology Assessment Programme (NETSCC)
General Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Commissioning Support Appraisals Service
  Department of Health,Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency (MHRA)
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Public Health Wales NHS Trust
  Scottish Medicines Consortium
Possible comparator manufacturer(s) Actavis UK (docetaxel, gemcitabine, paclitaxel, vinorelbine)
  AstraZeneca UK (gefitinib)
  Fresenius Kabi Oncology (paclitaxel, gemcitabine)
  Goldshield Pharmaceuticals (cisplatin)
  Hospira (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine)
  Lilly UK (gemcitabine, pemetrexed)
  Medac (UK) (docetaxel, gemcitabine, paclitaxel, vinorelbine)
  Mylan UK (gemcitabine)
  Pfizer Ltd (cisplatin)
  Pierre Fabre (vinorelbine)
  Roche Products (erlotinib)
  Sandoz (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine)
  Sanofi-Aventis Ltd (docetaxel)
  Sun Pharmaceuticals (carboplatin, gemcitabine)
  Teva UK Ltd (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
  Wockhardt UK (carboplatin, cisplatin, paclitaxel, vinorelbine)
Relevant research groups The British Thoracic Oncology Group (BTOG)
  Cochrane Lung Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research (NIHR)
  Research Institute for the Care of Older People


Key events during the development of the guidance:

Date Update
27 September 2012

The Appraisal Committeewere due to meet on Wednesday 13 February 2013to discuss the use of Cetuximab for the treatment of advanced non-small-cell lung cancer. The manufacturer has informed NICE that they have withdrawn their licence application to the EMA. Therefore, this appraisal is currently suspended.

Consequently the discussion of this appraisal at the committee meeting on the Wednesday 13 February 2013 has been cancelled.

15 May 2012 Following update from Manufacturer on regulatory timings this appraisal has been rescheduled and the first Appraisal Committee discussion will take place on 13 February 2013.
29 September 2009 Consultees and commentators informed that this appraisal will be delayed following the opinion issued after the July meeting of the Committee for Medicinal Products for Human (CHMP) of the European Medicines Agency (EMEA)
3 June 2008 Schedule updated.
9 March 2008 Consultees and commentators informed that this appraisal will be delayed due to ongoing regulatory discussions with regard to this license extension.

For further information on our processes and methods, please see our CHTE processes and methods manual